BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl) 2020;133:1696-702. [PMID: 32568866 DOI: 10.1097/CM9.0000000000000835] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Meng Y, Zhao T, Zhang Z, Zhang D. The role of hepatic microenvironment in hepatic fibrosis development. Annals of Medicine 2022;54:2830-2844. [DOI: 10.1080/07853890.2022.2132418] [Reference Citation Analysis]
2 Saab S, Pham N, Wu W, Dang L, Dang A, Yum J, Shim K, Wu S. Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients. Dig Dis Sci 2022;67:5309-14. [PMID: 35244827 DOI: 10.1007/s10620-022-07402-1] [Reference Citation Analysis]
3 Li J, Hu J, Li P, Wu Y, Wang Y, Ji M, Hua H, Ran W, Pan Y, Zhang S. Analysis of risk factors associated with endoscopic retrograde cholangiopancreatography for patients with liver cirrhosis: a multicenter, retrospective, clinical study. Chin Med J (Engl) 2022;135:2319-25. [PMID: 36103988 DOI: 10.1097/CM9.0000000000002248] [Reference Citation Analysis]
4 Niu X, Meng Y, Wang Y, Li G. Established new compound IMB16-4 self-emulsifying drug delivery systems for increasing oral bioavailability and enhancing anti-hepatic fibrosis effect. Biomedicine & Pharmacotherapy 2022;154:113657. [DOI: 10.1016/j.biopha.2022.113657] [Reference Citation Analysis]
5 Niu X, Meng Y, Wang Y, Li G. Established Liposome-Coated IMB16-4 Polymeric Nanoparticles (LNPs) for Increasing Cellular Uptake and Anti-Fibrotic Effects In Vitro. Molecules 2022;27:3738. [PMID: 35744862 DOI: 10.3390/molecules27123738] [Reference Citation Analysis]
6 Cao M, Fan J, Yang X, Shi M, Lin S, Chi X, Algalil FA. Exploration on Molecular Mechanism of Reversal Effect of Compound Danshen Tablets on Hepatic Fibrosis Based on Network Pharmacology. Applied Bionics and Biomechanics 2022;2022:1-6. [DOI: 10.1155/2022/7241719] [Reference Citation Analysis]
7 Gavril OI, Mitu RSGF. The Evolution of Liver Fibrosis in Patients with Viral C Infection Post Oral Antiviral Treatment. Internal Medicine 2022;19:53-9. [DOI: 10.2478/inmed-2022-0197] [Reference Citation Analysis]
8 Hammad S, Ogris C, Othman A, Erdoesi P, Schmidt-heck W, Biermayer I, Helm B, Gao Y, Piorońska W, D’alessandro LA, Theis FJ, Ebert MP, Klingmüller U, Hengstler JG, Dooley S, Mueller NS. Repeated toxic injuries of murine liver are tolerated through microsteatosis and mild inflammation.. [DOI: 10.1101/2022.01.12.476054] [Reference Citation Analysis]
9 Li W, Chen JY, Sun C, Sparks RP, Pantano L, Rahman RU, Moran SP, Pondick JV, Kirchner R, Wrobel D, Bieler M, Sauer A, Ho Sui SJ, Doerner JF, Rippmann JF, Mullen AC. Nanchangmycin regulates FYN, PTK2, and MAPK1/3 to control the fibrotic activity of human hepatic stellate cells. Elife 2022;11. [PMID: 35617485 DOI: 10.7554/eLife.74513] [Reference Citation Analysis]
10 Chen S, Zhu JY, Zang X, Zhai YZ. The Emerging Role of Ferroptosis in Liver Diseases. Front Cell Dev Biol 2021;9:801365. [PMID: 34970553 DOI: 10.3389/fcell.2021.801365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
11 Bhave S, Ho HK. Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1776. [PMID: 34944593 DOI: 10.3390/biomedicines9121776] [Reference Citation Analysis]
12 Li W, Chen JY, Sun C, Sparks RP, Pantano L, Rahman R, Moran SP, Pondick JV, Kirchner R, Wrobel D, Bieler M, Ho Sui SJ, Doerner JF, Rippmann JF, Mullen AC. Nanchangmycin regulates FYN, FAK and ERK to control the fibrotic activity of hepatic stellate cells.. [DOI: 10.1101/2021.10.08.463221] [Reference Citation Analysis]
13 Yoo SH, Lim TS, Lee HW, Kim JK, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee JI, Lee KS, Kim SU. Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. J Viral Hepat 2021;28:1362-72. [PMID: 34185929 DOI: 10.1111/jvh.13560] [Reference Citation Analysis]
14 Ehsan N, Sweed D, Elsabaawy M. Evaluation of HCV-related liver fibrosis post-successful DAA therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00129-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Zhao R, Gong XJ, Ge YQ, Zhao H, Wang LS, Yu HZ, Liu B. Use of Texture Analysis on Noncontrast MRI in Classification of Early Stage of Liver Fibrosis. Can J Gastroenterol Hepatol 2021;2021:6677821. [PMID: 33791254 DOI: 10.1155/2021/6677821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Stone RC, Chen V, Burgess J, Pannu S, Tomic-Canic M. Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response. Int J Mol Sci 2020;21:E8590. [PMID: 33202590 DOI: 10.3390/ijms21228590] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]